Symptomatic and functional remission in European patients with schizophrenia after paliperidone palmitate treatment (1-month and 3-month formulations)

被引：0
|
作者：
Savitz, A. [1 ]
Xu, H. [2 ]
Gopal, S. [1 ]
Nuamah, I. [2 ]
Hough, D. [1 ]
Hargarter, L. [3 ]
机构：
[1] Janssen Res & Dev, Cent Nervous Syst, Titusville, FL USA
[2] Janssen Res & Dev, Clin Biostats NJ, Titusville, FL USA
[3] Janssen Cilag, Med & Sci Affairs, Neuss, Germany
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2016年 / 26卷
关键词：
D O I：
10.1016/S0924-977X(16)31590-5
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.3.d.029
引用
收藏
页码：S546 / S547
页数：2
相关论文
共 50 条
  • [31] Differences of use between paliperidone palmitate 3 month and paliperidone palmitate 1 month in real practice, with psychotic patients.
    Escobedo-Aedo, P.
    Merayo-Cano, J.
    Mata Iturralde, L.
    Munoz Lorenzo, L.
    Ovejero, S.
    Sanchez Alonso, S.
    EUROPEAN PSYCHIATRY, 2022, 65 : S730 - S731
  • [32] Cost-effectiveness of 3-month paliperidone treatment for chronic schizophrenia in Spain
    Einarson, Thomas R.
    Bereza, Basil G.
    Llinares, Ignacio Garcia
    Moro, Beatriz Gonzalez Martin
    Tedouri, Fadi
    Van Impe, Kristel
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (10) : 1039 - 1047
  • [33] Population Pharmacokinetic Simulations of Dosing Windows and Missed Doses of Paliperidone Palmitate 3-month Formulation in Schizophrenia
    Gopal, Srihari
    Vermeulen, An
    Nandy, Partha
    Ravenstijn, Paulien
    Nuamah, Isaac
    Vidal, Jose Antonio Buron
    Savitz, Adam
    Hough, David
    Samtani, Mahesh N.
    Russu, Alberto
    BIOLOGICAL PSYCHIATRY, 2016, 79 (09) : 211S - 211S
  • [34] Pseudoparkinsonism and secondary suicidal ideation after 3-month paliperidone palmitate administration: a clinical case
    Fernandes, L. A. C.
    Serra, L.
    Lages, M.
    Almeida, D.
    Flores, J.
    Tome, C.
    Borja-Santos, N.
    EUROPEAN PSYCHIATRY, 2019, 56 : S474 - S475
  • [35] Three-month paliperidone palmitate - a new treatment option for schizophrenia
    Bernardo, Miquel
    Bioque, Miquel
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (07) : 899 - 904
  • [36] Use of paliperidone palmitate 3-month formulation in clinical practice: an extended study
    Romero Guillena, S. L.
    Plasencia Garcia de Diego, B. O.
    Gotor Sanchez-luengo, F.
    Garcia Salguero, M.
    EUROPEAN PSYCHIATRY, 2019, 56 : S264 - S264
  • [37] Use of paliperidone palmitate 3-month formulation: Effectiveness and functionality in clinical practice
    Romero Guillena, S. L.
    Navarro, R.
    Garcia de Diego, B. O. Plasencia
    Santamaria, O.
    Gotor Sanchez-Luengo, F.
    EUROPEAN PSYCHIATRY, 2018, 48 : S197 - S197
  • [38] Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study
    Savitz, Adam J.
    Xu, Haiyan
    Gopal, Srihari
    Nuamah, Isaac
    Ravenstijn, Paulien
    Janik, Adam
    Schotte, Alain
    Hough, David
    Fleischhacker, Wolfgang W.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2016, 19 (07):
  • [39] Caregiver Burden in Schizophrenia: Pooled Analysis of the Involvement Evaluation Questionnaire Data for Paliperidone Palmitate 3-month Formulation
    Gopal, Srihari
    Xu, Haiyan
    McQuarrie, Kelly
    Savitz, Adam
    Nuamah, Isaac
    Woodruff, Kimberly
    Mathews, Maju
    BIOLOGICAL PSYCHIATRY, 2016, 79 (09) : 213S - 213S
  • [40] Caregiver Burden In Schizophrenia: Pooled Analysis Of The Involvement Evaluation Questionnaire Data For Paliperidone Palmitate 3-Month Formulation
    Gopal, S.
    Xu, H.
    McQuarrie, K.
    Savitz, A.
    Nuamah, I
    Woodruff, K.
    Mathews, M.
    VALUE IN HEALTH, 2016, 19 (03) : A191 - A191
12345